ScoreHaematology

IPS-E: prognosis of asymptomatic early-stage CLL

Estimates the risk of needing treatment in early, asymptomatic chronic lymphocytic leukaemia.

Updated 31 October 2026

When to use it

Patients with Binet A or Rai 0–II CLL without treatment indication, to plan follow-up.

What it needs

  • Unmutated IGHVYes or no
  • Lymphocytes > 15 × 10⁹/LYes or no
  • Palpable lymph nodesYes or no

The points for each answer and the automatic total are in the app.

How to interpret it

IPS-E score
ResultInterpretation
≤ 0Low risk: treatment at 5 years ≈ 8%
1Intermediate risk: treatment at 5 years ≈ 28%
≥ 2High risk: treatment at 5 years ≈ 61%

Practical tip

It predicts time to first treatment, not survival: use CLL-IPI for that.

2 more practical tips in the app.

Reference

A support tool for healthcare professionals: it guides and does not replace clinical judgement.

Back to top